When Hariprasad Thangavel examined cancer cells under the microscope, he saw dark spots—tiny voids in the gelatin matrix where tumor cells had begun to chew through tissue, guided by tentacle-like structures called invadopodia. These weren’t just random breaks; they were the footprints of a silent messenger from fat tissue, one that could be reprogramming triple-negative breast cancer (TNBC) cells to spread. At the Hackensack Meridian Center for Discovery and Innovation and Georgetown University’s Lombardi Comprehensive Cancer Center, a team led by Jyothi Nagajyothi has uncovered a hidden dialogue between fat and cancer—one that could transform how we treat one of the most aggressive forms of breast cancer.
TNBC accounts for about 10–15% of all breast cancers and carries a poorer prognosis due to its lack of hormone receptors, making it unresponsive to many targeted therapies. But this new research reveals that the fat tissue surrounding tumors is far from a passive bystander. Instead, it releases microscopic messengers called adipomes—extracellular vesicles that travel from fat to cancer cells, delivering a specific "lipid code" that reprograms them. This code activates stress-response pathways, ramps up protein production, and jumpstarts mitochondrial activity, ultimately triggering the formation of invadopodia, the very structures that allow cancer to invade surrounding tissues and metastasize.
The breakthrough came when the team developed a novel purification technique—the first of its kind—capable of isolating pure adipomes from intact tissues, blood, and other fluids. This method, now the subject of a pending U.S. patent (US Patent App. 19/233,485), allowed researchers to trace the molecular journey of these vesicles with unprecedented clarity. Using human clinical samples from the Hackensack Meridian Health Network Biorepository and preclinical models, they confirmed that adipomes from cancer-associated fat tissue are fundamentally different from those in healthy tissue—acting not as inert carriers but as active orchestrators of the tumor microenvironment.
The implications are profound. For years, adipocytes were seen as mere lipid reservoirs, passive support cells in the breast. Now, they’re emerging as key players in cancer’s spread. "This work challenges the traditional view of tumor-adjacent adipocytes as passive lipid reservoirs and instead reveals their active and dynamic role as key orchestrators of the mammary TME," the researchers write. By intercepting the adipome signal, future therapies could potentially block metastasis before it begins—offering hope for earlier intervention in a disease that often evades current treatments.
With TNBC disproportionately affecting younger women and certain racial groups, including Black and Hispanic populations, this discovery opens a new front in the fight against health disparities in oncology. The team is now exploring ways to disrupt the lipid signaling cascade, aiming to develop therapies that could neutralize adipomes before they reprogram cancer cells. In a field where progress can feel incremental, this research offers something rare: a fresh path forward, hidden in plain sight within the body’s own fat.